Email this article Role of PDLIM4 and c-Src in breast cancer progression
- Authors: Kravchenko D.S.1,2, Frolova E.I.1, Kravchenko J.E.1,2, Chumakov S.P.1,2
-
Affiliations:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
- Engelhardt Institute of Molecular Biology
- Issue: Vol 50, No 1 (2016)
- Pages: 59-68
- Section: Reviews
- URL: https://journals.rcsi.science/0026-8933/article/view/162504
- DOI: https://doi.org/10.1134/S002689331601009X
- ID: 162504
Cite item
Open Access
Access granted
Subscription Access
Abstract
High heterogeneity is characteristic of oncology diseases, often complicating the choice of optimal anticancer treatment. One cancer type may combine tumors differing in histogenesis, genetic lesions, and mechanism of cell transformation. Differences in the mechanism of cell malignant transformation result in specifics of cancer cell metabolism and sensitivity to various agents, including anticancer treatments. Hence, the molecular subtype of a tumor is essential to know for choosing the optimal therapeutic strategy. The review considers the role actin-associated proteins and tyrosine kinases, in particular, PDLIM4 and Src kinase, play in the formation of pathological signaling pathways.
Keywords
About the authors
D. S. Kravchenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Engelhardt Institute of Molecular Biology
Author for correspondence.
Email: stepan@chumakov.email
Russian Federation, Moscow, 117997; Moscow, 117997
E. I. Frolova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: stepan@chumakov.email
Russian Federation, Moscow, 117997
J. E. Kravchenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Engelhardt Institute of Molecular Biology
Email: stepan@chumakov.email
Russian Federation, Moscow, 117997; Moscow, 117997
S. P. Chumakov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Engelhardt Institute of Molecular Biology
Email: stepan@chumakov.email
Russian Federation, Moscow, 117997; Moscow, 117997
Supplementary files
